PUBLICATION
SMC Laboratories is highly regarded worldwide as a consulting CRO that designs studies in line with the demands of pharmaceutical companies and research institutions.
In particular, in the NASH-HCC field, SMC is a highly regarded CRO, because of our unique STAM™ mice.
The results achieved with our STAM™ have been introduced in academic publications as well as scientific conferences.
Publications
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
No.49
International Journal of Molecular Medicine,
“The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice.” (Int J Mol Med, 44(6):2256-2264, 2019)
VIEW ARTICLE 
No.48
Science Translational Medicine,
“Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis” (Sci Transl Med., 11(520), 2019)
VIEW ARTICLE
No.47
Cells,
“Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis” (Cells, 8;8(11), 2019)
VIEW ARTICLE
No.46
International Journal of Molecular Sciences,
“The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma”(Int. J. Mol. Sci. , 20(20), 5237, 2019)
VIEW ARTICLE
No.45
Toxicological Sciences,
“Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis.”(Toxicol Sci., 170(2):273-282, 2019)
VIEW ARTICLE
No.44
Biochemistry,
“A Panel of Protein Kinase Chemosensors Distinguishes Different Types of Fatty Liver Disease” (Biochemistry, 58(37):3911-3917, 2019)
VIEW ARTICLE
No.43
Hepatology Communications,
“Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents“ (Hepatol Commun., 3(8): 1085–1097, 2019)
VIEW ARTICLE
No.42
International Journal of Gastroenterology,
"Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis" (International Journal of Gastroenterology, DOI: 10.11648/j.ijg.20190301.12, 2019)
VIEW ARTICLE
No.41
Experimental Animals,
"Analysis of amino acid profiles of blood over time and biomarkers associated with non-alcoholic steatohepatitis in STAM™ mice" (Exp Anim., DOI: 10.1538/expanim.18-0152, 2019)
VIEW ARTICLE
No.40
Frontiers in Genetics,
"Gene Expression and DNA Methylation Alterations During Non-alcoholic Steatohepatitis-Associated Liver Carcinogenesis" (Front Genet., May 29;10:486, 2019)
VIEW ARTICLE
No.39
Journal of Cellular and Molecular Medicine,
"The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis" (J Cell Mol Med., 23:1759-1770, 2019)
VIEW ARTICLE
No.38
Scientific Reports,
"Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan" (Sci Rep., Mar 8;9(1):4003, 2019)
VIEW ARTICLE